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Abstract
Background: The modulation of levodopa transport across the blood brain barrier by large neutral amino acids is
well documented. Protein limitation and protein redistribution diets may improve motor fluctuations in patients
with Parkinson’s disease but the pharmacokinetics and pharmacodynamics of levodopa and amino acids are highly
variable.
Methods: Clinical records of 1037 Parkinson’s disease patients were analyzed to determine the proportion of
patients with motor fluctuations related to protein interaction with levodopa. Motor fluctuations due to protein
interaction with levodopa were defined as dietary protein being associated with (i) longer time to levodopa
effectiveness, (ii) reduced benefit or duration of benefit, (iii) dose failures or (iv) earlier wearing off from a previously
effective dose. Dose failures, sudden, painful or behavioral wearing-off periods, gait freezing, nausea, hallucinations,
orthostasis, and dyskinesias were taken as markers of motor fluctuations, disease severity, and levodopa side effects
potentially influenced by protein.
Results: 5.9 % of Parkinson’s disease patients on levodopa, and 12.4 % with motor fluctuations on levodopa
correlated their fluctuations with the relative timing of levodopa and protein intake. These patients were younger at
disease onset, had worse motor fluctuations and had a higher incidence of family members with Parkinson’s
disease. Early wearing off or decreased dose efficacy were most commonly associated with protein interaction.
60 % of patients who modified their diets had weight loss.
Conclusions: This study suggests that clinically significant protein interaction with levodopa may occur mostly in a
subset of Parkinson’s disease patients with earlier disease onset and those with familial disease.
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Background
The reduction of the response to levodopa by amino
acids [1] and dietary protein [2] was first noted by Cot-
zias and colleagues. Dietary modifications have been
tested in Parkinson’s disease (PD) patients with motor
fluctuations. These include low [2–5] and high protein
diets [6, 7], addition of dietary large neutral amino acids
(LNAAs) [1, 8, 9] and redistribution of daily protein in-
take [3, 7, 10–16] (the majority of dietary protein is
normally consumed with dinner). The improvement in
clinical response varied from 30 % with protein redistri-
bution [11] to 82 % with low-protein diets [5]. The abil-
ity of patients to maintain such diets long-term was
variable [13, 16].
LNAAs (e.g. phenylalanine, tyrosine, and tryptophan)
have been shown to compete with levodopa for absorption
into the brain [17–20]. However, the data supporting a
role for plasma LNAA concentrations in motor fluctua-
tions is variable. Mean plasma levodopa levels were un-
changed with low protein and protein distribution diets
compared to a regular diet [3], but paradoxically higher
on high protein diets [6, 7]. Peak plasma levodopa concen-
trations were similarly variable [4, 6, 7, 21, 22]. While
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levels of LNAAs are lower after meals with lower protein
[3, 6, 7], the fluctuation in LNAAs with regular hospital
meals was small compared to the large swings in plasma
levodopa levels [9].
These studies were conducted on small populations
with heterogeneous data making it difficult to recom-
mend dietary modification to all PD patients [23]. In this
study we aimed to establish the prevalence and charac-
teristics of PD patients with clinically significant protein
interaction with levodopa leading to motor fluctuations.
Methods
Of all the patients seen at the Columbia University
Movement Disorders center between 2000 and 2012 by
P.M., B.F. and P.E.G., with available clinical records, a
total of 1037 patients with a clinical diagnosis of idio-
pathic PD by UK Brain bank criteria [24] were seen, and
their electronic clinical notes were reviewed and the pa-
rameters described below were extracted and tabulated.
Eight hundred seventy seven patients were on levodopa
and 435 of these had multiple clinic visits. All available
visit notes were reviewed and used to determine the
presence, and in a subset, the onset of the symptoms as
outlined for each parameter below.
Motor fluctuations were considered present if levo-
dopa dosing was reported by the patient to last less than
every 4 hours due to wearing off (“OFF”) of the motor
benefit derived from levodopa. Motor fluctuations re-
lated to protein interaction with levodopa (PIL) were
considered present when meals with higher protein food
groups (meat, eggs, dairy predominantly), were reported
by the patient to be followed by any of (i) longer time to
levodopa effectiveness, (ii) reduced benefit or duration
of benefit, (iii) dose failures or (iv) earlier wearing off
from a previously effective dose. Since patients may in-
consistently report protein ingestion effecting levodopa
effectiveness, and although all three movement disorders
neurologists typically ask about protein interaction in
patients with motor fluctuations, this may be an under-
estimate. Additionally, if patients reported that meals in
general resulted in decreased effectiveness of levodopa,
but did not specifically correlate this to the presence of
high protein content, they were not considered to have
PIL for the purpose of this study. This was done in order
to try and only address protein/amino acid effects re-
lated to competing transportation with levodopa across
the blood brain barrier and exclude potential issues re-
lated to any large meal leading to changes in gastric
emptying and thereby altering levodopa absorption from
the gut.
The age at motor onset was determined based on the
year patients reported onset of their motor symptoms
subtracted from their year of birth. The duration of dis-
ease was determined from the year of motor symptom
onset and the year of the last (i.e. most recent) clinic
note that was reviewed. The presence of freezing of gait
(as a marker of disease severity) was determined based
on patient report in the clinical history of the sensation
of the feet sticking to the ground on initiation of gait,
turning, in tight spaces or at destination or documented
by the movement disorders neurologist on examination.
Levodopa side effects (as potential markers influenced
by PIL) of nausea, hallucinations, and orthostasis (symp-
tomatic lightheadedness on standing) were deemed
present if documented in the clinical history and dyski-
nesias present if documented in the clinical history or
on movement disorders examination.
The year patients started levodopa therapy was avail-
able for 37/52 patients with PIL and 487/825 patients
without PIL, and was used to calculate the years on levo-
dopa based on the last recorded clinic note. In 15/52 pa-
tients the year they noted protein interaction led to
motor fluctuations was documented and was used to de-
termine the time of onset of PIL from motor symptom
onset and levodopa therapy initiation. The total daily
levodopa dose was calculated based on 100 % bioavail-
ability of carbidopa/levodopa immediate release (IR) and
carbidopa/levodopa/entacapone formulations [25] and
an estimated 70 % bioavailability of carbidopa levodopa
extended release (CR) formulation [26]. The presence of
concurrent dopamine agonist use (ropinirole, pramipex-
ole, rotigotine, pergolide or bromocriptine) or the use of
deep brain stimulator (DBS) surgery for the treatment of
their PD was also tabulated from the clinical charts. The
report of 1st and/or 2nd degree relatives with PD in the
social history was used for the calculation of the per-
centage with family history in the groups.
In order to exclude significant differences in age of on-
set or disease duration in the PIL vs no-PIL groups as a
cause for the changes we observed, two subgroups of
no-PIL patients were evaluated. The no-PIL group was
sorted by age of onset and for each patient in the PIL
group, five patients in the no-PIL group with the same
age of onset were randomly included in the age of onset
subgroup (no-PIL: age-ons). In the few cases where
enough patients with the exact age of onset were not
available, patients above and below that age were in-
cluded, keeping the mean age of onset as close as pos-
sible to that of the patient with PIL. This subset of
patients was then analyzed and compared to the PIL
group for the other parameters described above. In a
similar manner a subgroup of patients was also pro-
duced that included five randomly selected patients
without PIL with the same disease duration as each pa-
tient with PIL (no-PIL: dis-dur).
The Shapiro-Wilk test was applied for data normality
and statistical significance determined by chi-square or
Mann–Whitney test where appropriate. SPSS version 22
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(IBM) was used for statistical analysis and box plots.
The study was approved by the Columbia University In-
stitutional Review Board.
Results
Of the 1037 PD patients, 877 took levodopa, and 52/877
(5.9 %) met criteria for motor fluctuations related to PIL.
Patients reporting PIL were younger at motor symptom
onset, took higher maximal daily equivalent levodopa
doses, used more dopamine agonists, had longer disease
duration and levodopa use (Fig. 1a–e), and were younger
at their last clinic visit (62.2 ± 10.8 vs. 68.8 ± 10.5 years).
Gender ratio was similar in both groups (37 vs. 31 % fe-
male PIL vs. no-PIL patients). The percentage of patients
who had undergone DBS was also similar in both groups
(7.7 vs. 8.5 % PIL vs. no-PIL patients). PIL patients
reported more family members (first and/or second de-
gree relatives) with PD (p = 0.024; OR = 1.96; 95 % CI =
1.08–3.56) (Fig. 1f ). More PIL patients had dyskinesias
and freezing of gait, but there was no difference in nau-
sea, orthostasis or hallucinations (Fig. 2a).
Of the 52 patients with PIL, 26 (50 %) reported de-
creased efficacy of levodopa after protein intake, 15
(29 %) reported that protein intake led to wearing OFF
of a previously effective dose, 9 (17 %) reported dose
failures when levodopa and protein were taken concur-
rently, while one patient each reported delayed time to
motor improvement (ON state) and decreased length of
ON state time after protein. In PIL patients with data,
PIL onset was 12.9 ± 6.7 years after motor onset (range
3–26 years, N = 15) and 7.9 ± 7.7 years after starting








































































































































































































Fig. 1 General characteristics of all patients who exhibited protein interaction with levodopa a Age at motor onset, b duration of disease, c
maximal daily levodopa dose, d years on levodopa, e percentage of patients on a dopamine agonist and f percentage with first or second
degree relative with parkinsonism. (PIL; black bars) compared to those that did not (no-PIL: all; white bars) and subgroups of PIL patients with
motor fluctuations (no-PIL:mot-fluct; gradient bars) and no-PIL patients matched for disease-duration (no-PIL: dis-dur; light gray bars) and age-at-
motor-onset (no-PIL: age-ons; dark gray bars). The numbers of patients represented in each graph are inset. P values represent results of the
chi-square or Mann–Whitney test comparing each no-PIL group to the PIL group. Legend: PIL: protein interaction with levodopa, no-PIL: no
protein interaction with levodopa
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Twenty patients had documented dietary modifica-
tions ranging from decreased total daily protein intake
(15/20), redistribution of protein to the evening meal (2/
20), small frequent meals (1/20), decreased total protein
all taken only with the evening meal (1/20), and small
frequent meals with protein in the evening meal only (1/
20). Two patients had not changed their diets. The effi-
cacy of these changes on motor fluctuations was unfor-
tunately not adequately documented but 12/20 (60 %)
reported weight loss after changing their diet.
In PD patients with motor fluctuations, a population
much less likely to suffer from potential underreporting, 52/
421 (12.4 %) had PIL, with a greater frequency of dose fail-
ures, sudden OFFs, behavioral OFFs and painful OFFs com-
pared to no-PIL patients with motor fluctuations (Fig. 2b).
Hallucinations were less common in PIL patients compared
to no-PIL patients with motor fluctuations (Fig. 2a). The
duration of disease from time of onset of motor symptoms
(Fig. 1b) and the maximal daily levodopa dose (Fig. 1c) were
not statistically different between these groups. However, the
duration of levodopa use was longer in PIL patients (Fig. 1d).
The age at motor onset was earlier (Fig. 1a) and the percent
reporting a family history of PD remained higher in PIL pa-






































































































Fig. 2 a Motor and non-motor characteristics of all patients (black bars: PIL, white bars: no-PIL: all) and subgroups of no-PIL patients with motor
fluctuations (no-PIL: mot-fluct; gradient bars), or matched for disease-duration (no-PIL:dis-dur; light gray bars) or age-at-motor-onset (no-PIL:
age-ons; dark gray bars). b Characteristics of motor fluctuations in PIL patients compared to those with motor fluctuations in the no-PIL groups.
P values represent results of the chi-square or Mann–Whitney test comparing each no-PIL group to the PIL group. Legend: PIL: protein interaction
with levodopa, no-PIL: no protein interaction with levodopa, motor fluct: motor fluctuations, behav. OFFs: behavioral OFFs, FOG: freezing of gait,
dysk: dyskinesias, ortho.:orthostasis, halluc.: hallucinations
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To further examine the longer disease duration in PIL
patients, we performed a subgroup analysis by randomly
selecting, for every PIL patient, five no-PIL patients
matched for disease duration. In this subgroup (no-PIL:
dis-dur), age at motor onset was again significantly lower
in PIL patients (Fig. 1a), while duration of levodopa use
(Fig. 1d) and percentage on dopamine agonists (Fig. 1e)
were equivalent. Similarly to the whole-group results,
PIL patients in this subgroup took a higher levodopa
dose (Fig. 1c) and had higher frequency of motor com-
plications (Fig. 2) and family history of PD (p = 0.041;
OR = 1.94; 95 % CI = 1.02–3.67) (Fig. 1f ). Therefore, dif-
ferences in disease duration are unlikely to account for
the differences between PIL and no-PIL groups.
Younger-onset patients are known to have a higher in-
cidence of familial disease [27–29]. To determine
whether there was a familial component to PIL inde-
pendent of age, we matched PIL patients for age of onset
(Figs. 1 and 2; no-PIL: age-ons). Similar to the whole-
group comparison, the percentage of patients with PIL
reporting a family history of PD was higher (p = 0.045;
OR = 1.92; 95 % CI = 1.01–3.67) (Fig. 1f ).
Discussion
A significant protein interaction with levodopa associ-
ated with motor fluctuations was reported in a small
percentage of our patients: 5.9 % of our PD patients on
levodopa and 12.4 % of those on levodopa with motor
fluctuations. Almost 80 % of PIL patients either had de-
creased efficacy of their levodopa dose, or wore OFF
from a prior dose after protein ingestion. PIL patients
were younger at disease onset and reported a higher fre-
quency of familial PD, even when matched for disease
duration, maximal daily levodopa dose, or years of levo-
dopa use, suggesting that PIL could be familial. The
higher frequency of familial disease could not be
accounted for by an earlier age of onset alone.
PIL patients also had more severe motor fluctuations
with more frequent dose failures, sudden OFFs, behav-
ioral OFFs and painful OFFs compared to no-PIL pa-
tients with motor fluctuations, which could not be
accounted for by longer disease duration in the PIL
group. The severity of motor fluctuations could be due
to the interaction with levodopa reducing its effective-
ness and therefore leading to worsened signs and symp-
toms of the disease. However it could potentially be a
manifestation of differences in the disease process itself,
as PIL patients also had a greater frequency of freezing
of gait when compared with all no-PIL patients includ-
ing matched for disease duration and age of onset sub-
groups of no-PIL patients analyzed. Additionally the
mean onset of PIL from onset of motor symptoms was
12.9 years in the subset for which data was available, and
the mean duration of disease in the no-PIL group with
motor fluctuations was the same suggesting that they
had a long enough disease duration to develop such
complications were they to occur.
In the subset of patients with both the time of levo-
dopa initiation and the time of onset of PIL available, on
average 8 years elapsed between levodopa initiation and
PIL development. This suggests that allowing patients to
take levodopa with meals initially, to avoid developing
nausea, should not result in a significantly decreased
benefit. Additionally, limiting protein in the diet or
ingesting protein primarily with the evening meal led to
weight loss in a majority of PIL patients. As patients
with PD are already at an increased risk for weight loss
[30], limiting their diet can be problematic. Apomorph-
ine may be a better alternative to dietary protein restric-
tion or redistribution, unless it cannot be tolerated due
to nausea.
This study has the limitations of a retrospective study.
We might underestimate the prevalence of PIL due to
underreporting by patients or due to physicians not con-
sistently asking about protein-levodopa effects. However
the three fellowship trained movement disorders neur-
ologist routinely ask about protein related motor OFF
states, making the 12.4 % reported PIL in PD patients
with motor fluctuations, less likely to be an underesti-
mate, if at all. As patients often are not aware of the pat-
tern of their motor fluctuations in relation to
medications they may not notice the effect of meals or
protein on their motor function, and therefore not re-
port it. However the opposite is also not uncommon,
whereby patients only take levodopa on an empty stom-
ach as they are advised by their physicians or pharma-
cists of an interaction with protein. While this could be
a significant factor in reporting by patients early in the
disease course before onset of motor fluctuations, expe-
rienced patients with over 10 years disease duration, pa-
tients experiencing motor fluctuations, undergoing care
at a tertiary referral center, and having their medications
adjusted based upon their reports of motor fluctuations,
are likely to be more aware of factors that can precipi-
tate or worsen their motor function. In a population
with over 10 years of disease, the incidence of DBS sur-
gery was similar in both groups making it also unlikely
to account for no-PIL patients not noting protein inter-
action due to less severe motor fluctuations from DBS
therapy.
In clinical practice medications are always being ad-
justed based on patient’s subjective reports of their
motor function with levodopa dosing and would be a
factor whether this were a prospective or retrospective
study. While most patients reported high protein meals
causing the effect and not food in general (these patients
were excluded from the PIL group), we cannot account
for the effect delayed gastric emptying may potentially
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have had in the motor response in these patients or the
role fat content of meals may play in this process. How-
ever reduced benefit from a dose, earlier wearing off
from a previously effective dose and decreased duration
of benefit from a dose are less likely to be due to delayed
gastric emptying and accounted for the majority of pa-
tients effects (79 %) in this cohort. Calculations of dur-
ation of levodopa use, time to PIL onset from motor
symptom onset or levodopa initiation was limited to a
subset of patients. Additionally the efficacy of dietary
modifications could not be determined from records
available. However, the large numbers of patient records
analyzed (over 1000) and the availability of serial office
notes in about 50 % of these patients helps minimize
some of these concerns.
Conclusion
While it has been suggested that levodopa can be re-
duced in patients ingesting less protein [2, 5, 16], pa-
tients not responding to protein redistribution diets
were younger at onset and had longer duration of levo-
dopa use [16], as were our patients with PIL. This find-
ing, together with the unclear mechanism, the small
percentage of patients reporting PIL in our study, and
the weight loss experienced by those changing their di-
ets, raises the question as to whether dietary modifica-
tion should be recommended to all patients reporting
motor fluctuations, or as some suggest, to all patients
taking levodopa.
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